ASCO: NSCLC Therapy Guided by RRM1, ERCC1 Expression Yields No Survival Difference

Guiding treatment for non–small-cell lung cancer (NSCLC) using expression levels of the proteins RRM1 and ERCC1 led to no difference in either progression-free or overall survival, according to a study presented at the American Society of Clinical Oncology (ASCO) annual meeting.
Source: Cancer Network - Category: Cancer & Oncology Source Type: news